NZ294917A - Anilinoquinazoline derivatives, preparative method and antiproliferative medicaments - Google Patents
Anilinoquinazoline derivatives, preparative method and antiproliferative medicamentsInfo
- Publication number
- NZ294917A NZ294917A NZ294917A NZ29491795A NZ294917A NZ 294917 A NZ294917 A NZ 294917A NZ 294917 A NZ294917 A NZ 294917A NZ 29491795 A NZ29491795 A NZ 29491795A NZ 294917 A NZ294917 A NZ 294917A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pct
- date
- antiproliferative
- medicaments
- preparative method
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical class N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9422866A GB9422866D0 (en) | 1994-11-12 | 1994-11-12 | Aniline derivatives |
| GBGB9507308.6A GB9507308D0 (en) | 1995-04-07 | 1995-04-07 | Aniline derivatives |
| PCT/GB1995/002606 WO1996015118A1 (en) | 1994-11-12 | 1995-11-08 | Aniline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ294917A true NZ294917A (en) | 1999-02-25 |
Family
ID=26305974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ294917A NZ294917A (en) | 1994-11-12 | 1995-11-08 | Anilinoquinazoline derivatives, preparative method and antiproliferative medicaments |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5821246A (OSRAM) |
| EP (1) | EP0790986B1 (OSRAM) |
| JP (1) | JP4011109B2 (OSRAM) |
| AT (1) | ATE175962T1 (OSRAM) |
| AU (1) | AU703328B2 (OSRAM) |
| CA (1) | CA2200871C (OSRAM) |
| DE (1) | DE69507505T2 (OSRAM) |
| DK (1) | DK0790986T3 (OSRAM) |
| ES (1) | ES2128092T3 (OSRAM) |
| FI (1) | FI119933B (OSRAM) |
| IL (1) | IL115959A (OSRAM) |
| MX (1) | MX9702956A (OSRAM) |
| NO (1) | NO307178B1 (OSRAM) |
| NZ (1) | NZ294917A (OSRAM) |
| TW (1) | TW321649B (OSRAM) |
| WO (1) | WO1996015118A1 (OSRAM) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| TW321649B (OSRAM) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| US5932574A (en) * | 1995-04-27 | 1999-08-03 | Zeneca Limited | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| CZ297769B6 (cs) | 1996-06-27 | 2007-03-28 | Janssen Pharmaceutica N. V. | N-[4-(heteroarylmetyl)fenyl]-heteroarylaminy, zpusob jejich prípravy a jejich pouzití jako léciva |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DE19642529A1 (de) | 1996-10-15 | 1998-04-16 | Bayer Ag | Aminophenolderivate |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| SK146199A3 (en) | 1997-04-25 | 2000-06-12 | Janssen Pharmaceutica Nv | Farnesyltransferase inhibiting quinazolinones |
| US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| JP4327259B2 (ja) * | 1997-05-06 | 2009-09-09 | ワイス・ホールディングズ・コーポレイション | 多発性嚢胞腎の治療のためのキナゾリン化合物の使用 |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| US6323209B1 (en) | 1997-11-06 | 2001-11-27 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| ES2317688T3 (es) | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
| US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US6706721B1 (en) * | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| CA2333392A1 (en) | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
| US6399743B1 (en) | 1999-05-14 | 2002-06-04 | Dept. Of Veterans Affairs | Isolation and characterization of a rat epidermal growth factor related protein |
| IL147308A0 (en) * | 1999-06-30 | 2002-08-14 | Tularik Inc | Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| DE60037020T2 (de) * | 1999-07-09 | 2008-08-21 | Glaxo Group Ltd., Greenford | Anilinochinazoline als protein-tyrosin-kinasehemmer |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| EP1218356A1 (en) * | 1999-09-21 | 2002-07-03 | AstraZeneca AB | Quinazoline compounds and pharmaceutical compositions containing them |
| KR20020032612A (ko) * | 1999-09-21 | 2002-05-03 | 다비드 에 질레스 | 퀴나졸린 유도체 및 그의 의약으로서의 용도 |
| BR0015203A (pt) * | 1999-11-05 | 2002-07-16 | Astrazeneca Ab | Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um composto, e, processo para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| EP1274692B1 (en) * | 2000-04-07 | 2006-08-02 | AstraZeneca AB | Quinazoline compounds |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2001098277A2 (en) | 2000-06-22 | 2001-12-27 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| TWI307339B (en) * | 2000-06-30 | 2009-03-11 | Glaxo Group Ltd | Quinazoline ditosylate salt comprounds |
| EE05387B1 (et) | 2000-08-21 | 2011-02-15 | Astrazenecaab | KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine |
| JP2004511479A (ja) * | 2000-10-13 | 2004-04-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
| AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| HUP0401646A2 (hu) * | 2001-11-03 | 2004-12-28 | Astrazeneca Ab, | Tumorellenes hatású kinazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| ATE377009T1 (de) * | 2001-11-30 | 2007-11-15 | Osi Pharm Inc | Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum |
| MXPA04006260A (es) | 2001-12-24 | 2005-03-31 | Astrazeneca Ab | Derivados de quinazolina sustituidos como inhibidores de cinasas aurora. |
| CN1627944A (zh) | 2002-01-17 | 2005-06-15 | 神经能质公司 | 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂 |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| JP4703183B2 (ja) | 2002-07-15 | 2011-06-15 | シンフォニー エボルーション， インク． | 受容体型キナーゼモジュレーターおよびその使用方法 |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| DK1847539T3 (da) | 2002-12-24 | 2009-11-09 | Astrazeneca Ab | Quinazolin-derivater |
| WO2004069145A2 (en) * | 2003-02-07 | 2004-08-19 | Dr. Reddy's Laboratories Ltd. | Anticancer compounds, process for their preparation and pharmaceutical compositions containing them |
| AU2004232527A1 (en) * | 2003-04-16 | 2004-11-04 | Astrazeneca Ab | Chemical compounds |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| EP1636195A1 (en) * | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
| DE602004015108D1 (de) * | 2003-06-02 | 2008-08-28 | Astrazeneca Ab | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| EP1660479A1 (en) * | 2003-07-29 | 2006-05-31 | Astrazeneca AB | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
| JP4828421B2 (ja) | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| DK1667992T3 (da) * | 2003-09-19 | 2007-04-30 | Astrazeneca Ab | Quinazolinderivater |
| DE602004004811T2 (de) * | 2003-09-19 | 2007-11-22 | Astrazeneca Ab | Chinazolinderivate |
| MXPA06003341A (es) * | 2003-09-25 | 2006-06-08 | Astrazeneca Ab | Derivados de quinazolina. |
| EP2213661B1 (en) | 2003-09-26 | 2011-07-20 | Exelixis Inc. | c-Met Modulators and Methods of Use |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| EP1684762A4 (en) | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| SG141459A1 (en) | 2003-12-23 | 2008-04-28 | Pfizer | Novel quinoline derivatives |
| WO2005070900A1 (en) * | 2004-01-22 | 2005-08-04 | Altana Pharma Ag | N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors |
| EP1755394A4 (en) * | 2004-04-16 | 2009-08-05 | Smithkline Beecham Corp | METHOD OF TREATING CANCER |
| EP1746999B1 (en) | 2004-05-06 | 2011-11-16 | Warner-Lambert Company LLC | 4-phenylamino-quinazolin-6-yl-amides |
| AU2005256659A1 (en) * | 2004-06-28 | 2006-01-05 | Nycomed Gmbh | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
| ES2378772T3 (es) * | 2004-10-12 | 2012-04-17 | Astrazeneca Ab | Derivados de quinazolina |
| DE602005026865D1 (de) | 2004-12-14 | 2011-04-21 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| ATE521603T1 (de) * | 2005-02-26 | 2011-09-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| JP2006347936A (ja) | 2005-06-15 | 2006-12-28 | Bayer Cropscience Ag | 殺虫性ベンズアニリド類 |
| EP1928861B1 (en) | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| BR122018075851B1 (pt) | 2005-11-15 | 2022-01-11 | Array Biopharma Inc | Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos |
| US20100222344A1 (en) | 2005-12-02 | 2010-09-02 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2007099323A2 (en) * | 2006-03-02 | 2007-09-07 | Astrazeneca Ab | Quinoline derivatives |
| US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| AU2006345660A1 (en) | 2006-06-01 | 2007-12-06 | Japan As Represented By Director General Of Agency Of National Cancer Center | Tumor suppressor |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| EP2118075A1 (de) * | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| CA2703767A1 (en) | 2007-10-29 | 2009-05-07 | Natco Pharma Limited | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
| EA019709B1 (ru) | 2008-02-07 | 2014-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Спирогетероциклы и их применение в качестве лекарственных средств |
| ES2444128T3 (es) | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | Nueva SAL-554 |
| JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ，エルエルシー． | ５−リポキシゲナーゼ活性化タンパク質阻害剤 |
| US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
| AR075025A1 (es) | 2009-01-16 | 2011-03-02 | Bristol Myers Squibb Co | Sales de malato de n-(4-((6,7-bis(metiloxi) quinolin-4-il) oxi)fenil)-n'-(4-fluorofenil) ciclopropan-1,1-dicarboxamida y formas cristalinas de las mismas |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PT3351558T (pt) | 2009-11-13 | 2020-04-09 | Daiichi Sankyo Europe Gmbh | Material e métodos para tratamento ou prevenção de doenças associadas a her-3 |
| US20120156130A1 (en) | 2010-08-06 | 2012-06-21 | Thore Hettmann | Use of her3 binding agents in prostate treatment |
| KR20130016041A (ko) * | 2011-08-04 | 2013-02-14 | 재단법인 의약바이오컨버젼스연구단 | 신규한 아닐린 유도체 및 이의 용도 |
| CN102603496A (zh) * | 2011-09-26 | 2012-07-25 | 盘锦兴福化工有限公司 | 2,3—二氟苯丁醚的合成方法 |
| PE20160930A1 (es) | 2013-09-16 | 2016-09-03 | Astrazeneca Ab | Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso. |
| UY36547A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
| EP3283466A4 (en) * | 2015-04-16 | 2018-09-12 | Icahn School of Medicine at Mount Sinai | Ksr antagonists |
| JP6913076B2 (ja) | 2015-08-07 | 2021-08-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての２−（ヘタ）アリール−置換縮合ヘテロ環誘導体 |
| CN105461642B (zh) * | 2015-12-03 | 2017-03-22 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1505及其制备方法和应用 |
| CN105399689B (zh) * | 2015-12-03 | 2017-03-01 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1503及其制备方法和应用 |
| CN105418517B (zh) * | 2015-12-03 | 2017-03-22 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1509及其制备方法和应用 |
| CN108358798A (zh) * | 2018-02-12 | 2018-08-03 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成厄洛替尼中间体的方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3266990A (en) * | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| DE68917485T2 (de) * | 1988-01-23 | 1995-02-09 | Kyowa Hakko Kogyo Kk | Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen. |
| IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| CA2079113A1 (en) * | 1991-02-22 | 1992-08-23 | Calgene, Inc. | Seed plant fatty acyl reductase proteins and genes |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0584222B1 (en) * | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| EP0668280A1 (en) * | 1993-09-03 | 1995-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivative |
| GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| CA2183655C (en) * | 1994-02-23 | 2001-03-06 | Lee D. Arnold | 4-polycyclic amino-substituted quinazoline derivatives |
| AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| DK0682027T3 (da) * | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidinderivater med antiproliferativ virkning |
| TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (OSRAM) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| AU5108196A (en) * | 1995-03-20 | 1996-10-08 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
| MX9707453A (es) * | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| EP0819129B1 (en) * | 1995-04-03 | 2000-08-02 | Novartis AG | Pyrazole derivatives and processes for the preparation thereof |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5932574A (en) * | 1995-04-27 | 1999-08-03 | Zeneca Limited | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| EP0770080B1 (en) * | 1995-05-12 | 1999-07-14 | Neurogen Corporation | Novel deazapurine derivatives; a new class of crf1 specific ligands |
| EP0831829B1 (en) * | 1995-06-07 | 2003-08-20 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
| WO1996040648A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
| IL122855A (en) * | 1995-07-06 | 2004-08-31 | Novartis Ag | History of N-Phenyl (Alkyl) - 7H-Pyrolo [-3,2d] Pyrimidine - 4 Amine, their preparation and pharmaceutical preparations containing them |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9520822D0 (en) * | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| HUP9801177A3 (en) * | 1995-11-14 | 1998-11-30 | Pharmacia & Upjohn Spa | Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
-
1995
- 1995-10-27 TW TW084111357A patent/TW321649B/zh not_active IP Right Cessation
- 1995-11-08 US US08/836,362 patent/US5821246A/en not_active Expired - Lifetime
- 1995-11-08 JP JP51581696A patent/JP4011109B2/ja not_active Expired - Fee Related
- 1995-11-08 NZ NZ294917A patent/NZ294917A/xx not_active IP Right Cessation
- 1995-11-08 DE DE69507505T patent/DE69507505T2/de not_active Expired - Lifetime
- 1995-11-08 DK DK95936044T patent/DK0790986T3/da active
- 1995-11-08 EP EP95936044A patent/EP0790986B1/en not_active Expired - Lifetime
- 1995-11-08 WO PCT/GB1995/002606 patent/WO1996015118A1/en active IP Right Grant
- 1995-11-08 AT AT95936044T patent/ATE175962T1/de active
- 1995-11-08 ES ES95936044T patent/ES2128092T3/es not_active Expired - Lifetime
- 1995-11-08 CA CA002200871A patent/CA2200871C/en not_active Expired - Fee Related
- 1995-11-08 AU AU38130/95A patent/AU703328B2/en not_active Ceased
- 1995-11-08 MX MX9702956A patent/MX9702956A/es unknown
- 1995-11-12 IL IL11595995A patent/IL115959A/en not_active IP Right Cessation
-
1997
- 1997-05-07 FI FI971970A patent/FI119933B/fi not_active IP Right Cessation
- 1997-05-09 NO NO972152A patent/NO307178B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU703328B2 (en) | 1999-03-25 |
| JP4011109B2 (ja) | 2007-11-21 |
| NO972152D0 (no) | 1997-05-09 |
| CA2200871C (en) | 2008-08-19 |
| ES2128092T3 (es) | 1999-05-01 |
| IL115959A0 (en) | 1996-01-31 |
| MX9702956A (es) | 1997-06-28 |
| NO972152L (no) | 1997-05-12 |
| WO1996015118A1 (en) | 1996-05-23 |
| AU3813095A (en) | 1996-06-06 |
| FI971970A0 (fi) | 1997-05-07 |
| EP0790986B1 (en) | 1999-01-20 |
| TW321649B (OSRAM) | 1997-12-01 |
| DE69507505T2 (de) | 1999-06-02 |
| US5821246A (en) | 1998-10-13 |
| DK0790986T3 (da) | 1999-09-13 |
| IL115959A (en) | 2004-06-20 |
| JPH10508616A (ja) | 1998-08-25 |
| FI971970A7 (fi) | 1997-05-07 |
| EP0790986A1 (en) | 1997-08-27 |
| DE69507505D1 (de) | 1999-03-04 |
| CA2200871A1 (en) | 1996-05-23 |
| NO307178B1 (no) | 2000-02-21 |
| ATE175962T1 (de) | 1999-02-15 |
| FI119933B (fi) | 2009-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ294917A (en) | Anilinoquinazoline derivatives, preparative method and antiproliferative medicaments | |
| IL151626A0 (en) | Quinazoline compounds | |
| TW345575B (en) | Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound | |
| GB2338957B (en) | N-heterocyclic derivatives as nos inhibitors | |
| PL326203A1 (en) | (methylsulphonyl)phenyl-2-(5)-furanones as cox-2 inhibitors | |
| DE69729946D1 (de) | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia | |
| IL96407A0 (en) | Diazine derivatives | |
| AP9901435A0 (en) | Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors. | |
| HUT67434A (en) | Fluoroalkoxy-benzylamino derivatives of nitrogen containing heterocycles and pharmaceutical compositions containing them and process for their production | |
| GB9603095D0 (en) | Quinazoline derivatives | |
| GB9113628D0 (en) | Heterocyclic derivatives | |
| EA199700098A1 (ru) | Производные индола, пригодные для лечения остеопороза | |
| DK0766696T3 (da) | Thiazolidinderivater, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser | |
| PL306402A1 (en) | Thiazole derivatives, method of obtaining them and pharmaceutical preparations containing such derivatives | |
| AU5644296A (en) | Novel heterocyclic chemistry | |
| PL318459A1 (en) | N-substituted derivatives of azabicycoheptane, method of obtaining them and their application | |
| DK0675895T3 (da) | Etoposidderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemiddel og anvendelse deraf til fremstilling af et lægemiddel til anticancerbehandling | |
| NO972450L (no) | Substituerte 2-(fosfinyloksymetyl)-1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metode for anvendelse derav | |
| JO1648B1 (en) | Nitrogen compounds | |
| JO1697B1 (en) | Pyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |